Fresenius SE KGaA Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Michael Sen

Chief Executive Officer (CEO)

€7.0m

Compensación total

Porcentaje del salario del CEO	24.0%
Permanencia del CEO	3.1yrs
Participación del CEO	n/a
Permanencia media de la dirección	1.4yrs
Promedio de permanencia en la Junta Directiva	6.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Michael Sen en comparación con los beneficios de Fresenius SE KGaA?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	€7m	€2m	€353m
Sep 30 2023	n/a	n/a	€941m
Jun 30 2023	n/a	n/a	€1b
Mar 31 2023	n/a	n/a	€1b
Dec 31 2022	€5m	€1m	€1b
Sep 30 2022	n/a	n/a	€1b
Jun 30 2022	n/a	n/a	€2b
Mar 31 2022	n/a	n/a	€2b
Dec 31 2021	€2m	€755k	€2b

Compensación vs. Mercado: La compensación total de Michael($USD7.53M) está por encima de la media de empresas de tamaño similar en el mercado Swiss ($USD5.44M).

Compensación vs. Ingresos: La compensación de Michael ha aumentado más de un 20%, mientras que los beneficios de la empresa han caído más de un 20% en el último año.

CEO

Michael Sen (55 yo)

3.1yrs

Permanencia

€6,992,000

Compensación

Mr. Michael Sen is Chairman of the Supervisory Board at Fresenius Medical Care AG & Co. KGaA from July 14, 2023. He is Chief Executive Officer & President - Fresenius Management SE at Fresenius SE & Co. KG...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Michael Sen	CEO, President & Chairman of Management Board - Fresenius Management SE	3.1yrs	€6.99m	sin datos
Sara Hennicken	CFO & Member of the Management Board - Fresenius Management SE	1.7yrs	€2.39m	sin datos
Pierluigi Antonelli	Member of Management Board of Fresenius Management SE & CEO of Fresenius Kabi	1.2yrs	€3.12m	sin datos
Michael Moser	Member of Management Board of Fresenius Management SE	less than a year	€1.62m	sin datos
Robert Moller	Member of the Management Board of Fresenius Management SE	less than a year	€1.42m	sin datos
Markus Georgi	Senior Vice President of Investor Relations	9.1yrs	sin datos	sin datos
Matthias Link	Senior Vice President Corporate Communications	no data	sin datos	sin datos

1.4yrs

Permanencia media

48.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de FRE no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Gerd Krick	Honorary Chairman of Supervisory Board	3yrs	€219.00k	sin datos
Michael Diekmann	Independent Deputy Chairman of the Supervisory Board	9yrs	€320.00k	sin datos
Wolfgang Kirsch	Independent Chairman of Supervisory Board	4.3yrs	€560.00k	sin datos
Konrad Kölbl	Independent Member of Supervisory Board	16.8yrs	€185.00k	sin datos
Grit Genster	Independent Deputy Chairperson of the Supervisory Board	4.3yrs	€310.00k	sin datos
D. Albrecht	Independent Member of Supervisory Board	13.3yrs	€180.00k	sin datos
Iris Low-Friedrich	Independent Member of Supervisory Board	8yrs	€180.00k	sin datos
Susanne Zeidler	Independent Member of the Supervisory Board	3yrs	€290.00k	sin datos
Frauke Lehmann	Independent Member of Supervisory Board	8yrs	€180.00k	sin datos
Oscar De Paco	Independent Member of Supervisory Board	8yrs	€180.00k	sin datos
Bernd Behlert	Independent Member of Supervisory Board	5.7yrs	€215.00k	sin datos
Christoph Zindel	Independent Member of Supervisory Board	2yrs	€220.00k	sin datos

6.8yrs

Permanencia media

63.5yo

Promedio de edad

Junta con experiencia: La junta directiva de FRE se considera experimentada (6.8 años de antigüedad promedio).

Fresenius SE KGaA Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Fresenius SE & Co. KGaA, Annual General Meeting, May 17, 2023

Fresenius SE Announces Chief Financial Officer Changes

Fresenius SE & Co. KGaA Announces Michael Sen as CEO on October 1, 2022 Succeeding Stephan Sturm

Fresenius SE & Co. KGaA, Annual General Meeting, May 21, 2021

Recent updates

PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

New major risk - Financial position

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC completed the acquisition of EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE).

German Fresenius Reportedly Seeks to Sell Vamed Reha

Fresenius SE & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 14, 2024

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC agreed to acquire EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE) for €500 million.

Third quarter 2023 earnings released: €0.72 loss per share (vs €0.57 profit in 3Q 2022)

Fresenius SE & Co. KGaA to Report Q2, 2024 Results on Jul 31, 2024

KKR in Talks to Buy Eugin from Fresenius

Fresenius Reportedly Plans to Offload Digital Subsidiary Curalie

New major risk - Financial position

Second quarter 2023 earnings released: EPS: €0.14 (vs €0.68 in 2Q 2022)

Fresenius SE & Co. KGaA to Report Q3, 2023 Results on Nov 02, 2023

Fresenius Se & Co. Kgaa Proposes Dividend for 2022

Upcoming dividend of €0.92 per share at 3.3% yield

First quarter 2023 earnings released: EPS: €0.61 (vs €0.74 in 1Q 2022)

Fresenius SE & Co. KGaA to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings released: EPS: €2.44 (vs €3.26 in FY 2021)

Fresenius SE & Co. KGaA, Annual General Meeting, May 17, 2023

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

Third quarter 2022 earnings released: EPS: €0.57 (vs €0.74 in 3Q 2021)

Brookfield Reportedly Drops Out of Race to Buy Healius

Fresenius SE Announces Chief Financial Officer Changes

Fresenius SE & Co. KGaA Announces Michael Sen as CEO on October 1, 2022 Succeeding Stephan Sturm

Second quarter 2022 earnings released: EPS: €0.68 (vs €0.84 in 2Q 2021)

Healius Reportedly Launches Day Surgery Sale Process

Fresenius Kabi Introduces Generic Iodixanol Contrast Media Agent

Upcoming dividend of €0.92 per share

First quarter 2022 earnings released: EPS: €0.74 (vs €0.78 in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Fresenius SE & Co. KGaA Provides Earnings Guidance for the Year 2022

Third quarter 2021 earnings released: EPS €0.74 (vs €0.77 in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.84 (vs €0.74 in 2Q 2020)

Upcoming dividend of €0.88 per share

First quarter 2021 earnings released: EPS €0.78 (vs €0.82 in 1Q 2020)

Full year 2020 earnings released: EPS €3.06 (vs €3.38 in FY 2019)

Fresenius SE & Co. KGaA to Report Q1, 2021 Results on May 07, 2021

Fresenius SE & Co. KGaA, Annual General Meeting, May 21, 2021

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad